FDA Approves Niraparib Plus Abiraterone for BRCA2+ Prostate Cancer as the First Precision Therapy

Preoperative Radiation May Improve Antitumor Immune Response in HR+ HER2- Breast Cancer

Oral SERD Giredestrant Cuts Risk of Invasive Recurrence by 30% in Early ER+ Breast Cancer

Tucatinib Combination Cuts Progression Risk by 36% in HER2+ Metastatic Breast Cancer

GSK’s ADC Risvutatug Rezetecan Earns FDA Orphan Drug Status for Small Cell Lung Cancer

CAR T Anito cel Delivers Deep, Durable Responses in R&R Multiple Myeloma

Ribociclib Maintains Long-Term Disease Control in HR+ HER2 Metastatic Breast Cancer

Lunsumio Combo Deliver High Response Rates in Follicular and Large B-Cell Lymphomas

Colibactin’s Molecular Blueprint Exposes How a Gut Microbial Toxin Triggers Colorectal Cancer

Enozertinib Shows Strong Systemic and CNS Activity in EGFR Exon 20+ NSC Lung Cancer

Blood-Based cfDNA Test Demonstrates Potential for Detecting Lung Cancer in Nonsmokers

Nanotherapy Reprograms Glioblastoma Immunity Through Nose-to-Brain Delivery

Lung Organoids Offer a Revolutionary Path to Transform Drug Testing and Cancer Therapies

FDA Approves Durvalumab as First Perioperative Immunotherapy for GEJ Cancers

FDA Approves Keytruda–Padcev Combo as First Perioperative Treatment for Bladder Cancer

Sevabertinib Wins FDA Approval with Strong Responses in HER2+ NSC Lung Cancer

FDA Approves Epcoritamab-bysp as the First Bispecific Antibody for Follicular Lymphoma

FDA Approves Ziftomenib as a New Targeted Option for NPM1+ Acute Myeloid Leukemia

Novartis Invests $23 Billion to Boost Radioligand Manufacturing Capacity in Carlsbad

Lenvatinib Plus Everolimus Improves Outcomes After PD-1 Failure in Kidney Cancer

Radioligand Therapy Pluvicto Reduces Progression Risk by 28% in mHS Prostate Cancer

ctDNA Blood Test Guides Chemotherapy Decisions for Tailored Colon Cancer Treatment

DeLLphi-303: Tarlatamab Plus Chemo Achieves 71% Response in ES Small-Cell Lung Cancer

ESMO’s Road Map for Safe and Effective Use of AI-LLMs in Cancer Care: 23 Rules from 20 Experts

Ribociclib Extends Disease-Free Survival Beyond Treatment in HR+/HER2– Early Breast Cancer

Trodelvy Emerges as Potential New Standard for First-Line Metastatic TN Breast Cancer

Datroway Extends Survival by 5 Months in Metastatic Triple-Negative Breast Cancer

Lenvatinib Plus Pembrolizumab Delivers Durable 5-Year Survival in Endometrial Carcinoma

AI Analysis of Thymic Health Predicts Immunotherapy Success, Cutting Death Risk by 44%

Disarming Prostate Cancer: Dual Enzyme Blockade Weakens Tumors and Boosts Drug Response